MemoryPhase 2NCT07251985
Cognitive Effects of Bioavailable Curcumin
A Phase 2 study testing Curcumin in people with Memory and Cognitive Function Decline, run by University of California, Los Angeles.
Trial summary
An estimated 50% of older adults complain of memory changes that worsen as they age. Although numerous commercially available dietary supplements claim cognitive benefits, relatively few well-designed, longitudinal, placebo-controlled studies have rigorously evaluated their effects on cognitive performance. Read more about this study
- Who is it for?
- Ages 50 to 85 yearsHealthy volunteers can take part
- Conditions the study is for
- Memory, Cognitive Function Decline
- What is being tested?
- Curcumin
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 0 participants
- Where
- No sites listed yet
- Study dates
- 1 Apr 2026to 15 Apr 2026
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 85 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Presence of age-related memory complaints;
- Male or female aged 50 to 85 years of age at Visit 1.
- performance on MoCA test of >= 18 (Milani et al, 2018)
- Ability to perform normal daily activities independently (which excludes a diagnosis of dementia).
- Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.
- Agreement to participate in the entire study, which could last either 6 or 12 months depending on results of the interim analysis.
Show all 10Show fewer
- Adequate visual and auditory acuity for cognitive testing.
- Screening laboratory tests that do not show significant medical problems that might interfere with study participation or impact cognitive test results.
- Psychotropic medication, if used, should be stable for at least 2 weeks prior to randomization.
- Agreement to avoid taking any curcumin, turmeric supplements or cognitive enhancing medicines or supplements during the course of the study.
Who cannot join
- Allergy to curcumin
- Presence of a condition or abnormality that in the opinion of the site Principal Investigator would compromise the safety of the patient or the quality of the data.
- Significant cerebrovascular disease or Alzheimer disease or any other dementia.
- Neurological or physical illnesses that can produce cognitive deterioration.
- History of myocardial infarction within the previous year or unstable cardiac disease.
- Uncontrolled hypertension (systolic BP > 170 or diastolic BP > 100); significant liver or pulmonary disease, or cancer;
Show all 13Show fewer
- Current diagnosis of any major psychiatric disorder according to the DSM-IV TR criteria with a change in medication or clinical symptoms with the last 3 months prior to screening (APA, 2000).
- History of alcoholism or substance addiction in the last 15 years.
- Current treatment for seizure disorder;
- Abnormal laboratory values with clinical significance in the opinion of the site Principal Investigator.
- Current unstable medical illness including delirium, worsening congestive heart failure, unstable angina, recent myocardial infarctions, acute infectious disease, severe renal or hepatic failure, severe respiratory disease, metastatic cancer, or other conditions that, in the Principal Investigator's opinion, could interfere with the analysis of safety and efficacy in this study.
- A 2-week washout is required prior to baseline for any of the following: curcumin or turmeric supplements, any anti-inflammatory medication other than occasional use (e.g., once per week).
- The subject may not be an immediate family member (e.g., spouse, parent, child, sibling) of personnel directly affiliated with this study, the study site or study funding agency.
About this study
An estimated 50% of older adults complain of memory changes that worsen as they age. Although numerous commercially available dietary supplements claim cognitive benefits, relatively few well-designed, longitudinal, placebo-controlled studies have rigorously evaluated their effects on cognitive performance.
In a previous double-blind, randomized, placebo-controlled, 18-month clinical trial in middle-aged and older non-demented adults, the investigators found that a bioavailable form of curcumin taken orally twice a day showed greater gains on specific measures of memory and attention relative to placebo. Although the investigators found significant between-group curcumin/placebo differences with moderate effect sizes, the sample size (n=40) was small. The present adequately powered, randomized, double-blind, placebo-controlled study will evaluate the effect of daily consumption of bioavailable curcumin on measurable changes in cognitive performance in non-demented middle-aged and older adults.
- Conditions
- Memory, Cognitive Function Decline
- Being tested
- Curcumin, Placebo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CurcuminDietary supplement
Theracurmin Super TS-P1 capsules containing 75 mg in total of curcumin will be administered orally (swallowed with water) twice a day (during breakfast and dinner) for 12 months
PlaceboOther
Placebo
| Study group | Role | What they receive |
|---|---|---|
| Theracurmin Super TS-P1 capsules containing 75 mg in total of curcumin will be administered orally) | Active comparator | Not described Receives: Dietary Supplement: Curcumin |
| Placebo | Placebo comparator | Not described Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Memory
The primary endpoint will be a memory domain score calculated from the Consistent Long Term Recall score of the Buschke Selective Reminding Test (SRT)
Measured: 12 months
Memory
Delayed Recall score of the Brief Visual Memory Test-Revised (BVMT-R).
Measured: 12 months
Secondary outcomes (14)
Cognitive function test
NIH TOOLBOX computerized set of cognitive tests
Measured: 12 months
PROMIS Cognitive Function
Short Form 20a is a standardized questionnaire designed to assess an individual's self-reported cognitive abilities and problems over the past 7 days. It includes 20 items and is part of the Patient-Reported Outcomes Measure. The instrument produces a T-score standardized to the PROMIS metric. T-scores typically range from 20 to 80, with a population mean of 50 and standard deviation of 10.
Measured: 12 months
Self-reported depression symptoms
Measured by Beck Depression Inventory (BDI). A 21-item self-report questionnaire assessing the severity of depressive symptoms. Total scores range from 0 to 63, with higher scores indicating more severe depression (i.e., a worse outcome).
Measured: 12 months
Blood levels of curcumin
(to ensure adherence to protocol)
Measured: 12 months
Inflammation and neurodegenerative markers
such as, TNF-α, C-reactive protein
Measured: 12 months
metabolic markers
such as fasting glucose, insulin, C-peptide, glucagon, glucose-dependent-insulinotropic-polypeptide (GIP), HbA1C, and HOMA-IR index and lipid markers
Measured: 12 months
Quality of life
Quality of life, SF-36: The SF-36 is a multi-purpose survey designed to capture adult patients' perceptions of their own health and well-being. It measures each of the following eight health domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health (about 15 minutes).
Measured: 12 months
Body composition
Body composition will be assessed using an InBody bioelectrical impedance analysis (BIA) device.
Measured: 12 months
APOE-4 carrier status
APOE-4 carrier status will be determined through genetic testing to identify whether participants possess at least one copy of the APOE 4 allele, a genetic risk factor associated with Alzheimer's disease.
Measured: 12 months
Sleep quality
Pittsburgh Sleep Quality Index: PSQI will be employed to assess sleep quality. The PSQI is a widely recognized self-report questionnaire that evaluates sleep quality over a one-month interval. The PSQI comprises 19 self-rated items and an additional 5 items rated by bed partners or roommates. The self-rated items are used to calculate the total score, which ranges from 0 to 21. Each item on the PSQI is scored on a scale of 0 to 3, with 3 reflecting the highest level of dysfunction or disturbance. The scores of these items are then summed to compute a global PSQI score. A global PSQI score greater than 5 suggests significant sleep difficulties. A higher total score is indicative of poorer sleep quality.
Measured: 12 months
Fatigue
Fatigue (as assessed by PROMIS-Fatigue Scale, Short Form 8 items): The NIH developed the Patient Reported Outcomes Measurement Information System (PROMIS®). The PROMIS Fatigue scale assesses a range of self-reported symptoms, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The fatigue short forms are universal rather than disease-specific and assess fatigue over the past seven days (5 minutes).
Measured: 12 months
The Trail Making Test (TMT)
The Trail Making Test (TMT) is one of the most popular neuropsychological tests and is included in most test batteries. The TMT provides information on visual search, scanning, speed of processing, mental flexibility, and executive functions.
Measured: 12 months
Verbal Fluency Test
The Verbal Fluency Test, consisting of the FAS, PRW, and CFL phonemic fluency subtests, will be administered across three distinct time points to reduce practice effects and to allow for a more reliable assessment of longitudinal change in executive function and lexical retrieval. Administering different letter sets at each visit minimizes familiarity with specific stimuli and provides a more valid evaluation of verbal generativity and cognitive flexibility over time.
Measured: 12 months
Category Fluency Test
The Category Fluency Test, including the Animal Naming, Fruits and Vegetables Naming, and Cities and Towns Naming subtests, will be administered across three time points to assess semantic fluency while minimizing practice effects. Using a different semantic category at each visit reduces familiarity with specific item sets and provides a more accurate longitudinal measure of semantic memory retrieval, lexical access, and executive functioning.
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Nov 2025
- Study start1 Apr 2026
- Primary completion15 Apr 2026
- Study completion15 Apr 2026
Why it stopped: Sponsor withdrew.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MemoryStudies of the same condition, open and under way.
- More trials run by University of California, Los AngelesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of California, Los Angeles
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Zhaoping Li, University of California, Los Angeles
- Investigators
- Zhaoping Li, Principal investigator, University of California, Los Angeles
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07251985
- Sponsor's protocol ID
- 25-1154
- Status last verified
- Apr 2026
- First submitted
- 13 Nov 2025
- Last updated
- 1 May 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Cognitive Effects of Bioavailable Curcumin
- ClinicalTrials.gov ID
- NCT07251985
- Acronym / sponsor ID
- 25-1154
- Conditions
- Memory, Cognitive Function Decline
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: Sponsor withdrew.
- Enrolment
- 0 participants (actual)
- Lead sponsor
- University of California, Los AngelesUniversity, hospital or other
- Study start
- 1 Apr 2026 (actual)
- Primary completion
- 15 Apr 2026 (actual)
- Study completion
- 15 Apr 2026 (actual)
- First posted
- 26 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
An estimated 50% of older adults complain of memory changes that worsen as they age. Although numerous commercially available dietary supplements claim cognitive benefits, relatively few well-designed, longitudinal, placebo-controlled studies have rigorously evaluated their effects on cognitive performance.
In a previous double-blind, randomized, placebo-controlled, 18-month clinical trial in middle-aged and older non-demented adults, the investigators found that a bioavailable form of curcumin taken orally twice a day showed greater gains on specific measures of memory and attention relative to placebo. Although the investigators found significant between-group curcumin/placebo differences with moderate effect sizes, the sample size (n=40) was small. The present adequately powered, randomized, double-blind, placebo-controlled study will evaluate the effect of daily consumption of bioavailable curcumin on measurable changes in cognitive performance in non-demented middle-aged and older adults.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Theracurmin Super TS-P1 capsules containing 75 mg in total of curcumin will be administered orally) | Active comparator | Dietary Supplement: Curcumin |
| Placebo | Placebo comparator | Other: Placebo |
Who may qualify
- Ages
- 50 to 85 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- Presence of age-related memory complaints;
- Male or female aged 50 to 85 years of age at Visit 1.
- performance on MoCA test of >= 18 (Milani et al, 2018)
- Ability to perform normal daily activities independently (which excludes a diagnosis of dementia).
- Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.
Key exclusion criteria (13 listed)
- Allergy to curcumin
- Presence of a condition or abnormality that in the opinion of the site Principal Investigator would compromise the safety of the patient or the quality of the data.
- Significant cerebrovascular disease or Alzheimer disease or any other dementia.
- Neurological or physical illnesses that can produce cognitive deterioration.
- History of myocardial infarction within the previous year or unstable cardiac disease.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CurcuminTheracurmin Super TS-P1 capsules containing 75 mg in total of curcumin will be administered orally (swallowed with water) twice a day (during breakfast and dinner) for 12 months | Dietary supplement | Theracurmin Super TS-P1 capsules containing 75 mg in total of curcumin will be administered orally) |
| PlaceboPlacebo | Other | Placebo |
Primary outcome
Memory
Time frame: 12 months
The primary endpoint will be a memory domain score calculated from the Consistent Long Term Recall score of the Buschke Selective Reminding Test (SRT)
Memory
Time frame: 12 months
Delayed Recall score of the Brief Visual Memory Test-Revised (BVMT-R).
14 secondary outcomes
Cognitive function test
Time frame: 12 months
PROMIS Cognitive Function
Time frame: 12 months
Self-reported depression symptoms
Time frame: 12 months
Blood levels of curcumin
Time frame: 12 months
Inflammation and neurodegenerative markers
Time frame: 12 months
metabolic markers
Time frame: 12 months
Quality of life
Time frame: 12 months
Body composition
Time frame: 12 months
APOE-4 carrier status
Time frame: 12 months
Sleep quality
Time frame: 12 months
Fatigue
Time frame: 12 months
The Trail Making Test (TMT)
Time frame: 12 months
Verbal Fluency Test
Time frame: 12 months
Category Fluency Test
Time frame: 12 months
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 May 2026.
Related trials for Memory
Active, not recruitingPhase 4
A Study Testing How Well the Drug Extract of Ginkgo Biloba Leaves Tablets Works for People With Memory or Thinking Problems After a Stroke When Added to Standard Treatment
Ischemic Stroke Hospitalized, Impairment, Cognitive
Recruiting
OCT-Angiography and Adaptive Optics in Patients With Memory Impairment
Amnesia, Alzheimer Disease
RecruitingPhase 4
Blood Pressure Reduction to Limit the Evolution of Vascular Brain Lesions in Elderly Individuals
Cerebrovascular Disorders
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
Recruiting
SAINT® Therapy for Memory Problems in Older Adults With Treatment-Resistant Depression
Depressive Disorder, Treatment-Resistant, Memory Deficits
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Zhaoping Li principal investigator
University of California, Los Angeles
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Curcumin in people with Memory and Cognitive Function Decline, run by University of California, Los Angeles.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 1 May 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Memory (time frame: 12 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 May 2026.